Read by QxMD icon Read

Joaquim bellmunt

Andrea Necchi, Guru Sonpavde, Salvatore Lo Vullo, Daniele Giardiello, Aristotelis Bamias, Simon J Crabb, Lauren C Harshman, Joaquim Bellmunt, Ugo De Giorgi, Cora N Sternberg, Linda Cerbone, Sylvain Ladoire, Yu-Ning Wong, Evan Y Yu, Simon Chowdhury, Gunter Niegisch, Sandy Srinivas, Ulka N Vaishampayan, Sumanta K Pal, Neeraj Agarwal, Ajjai Alva, Jack Baniel, Ali-Reza Golshayan, Rafael Morales-Barrera, Daniel W Bowles, Matthew I Milowsky, Christine Theodore, Dominik R Berthold, Gedske Daugaard, Srikala S Sridhar, Thomas Powles, Jonathan E Rosenberg, Matthew D Galsky, Luigi Mariani
BACKGROUND: The available prognostic models for overall survival (OS) in patients with metastatic urothelial carcinoma (UC) have been derived from clinical trial populations of cisplatin-treated patients. OBJECTIVE: To develop a new model based on real-world patients. DESIGN, SETTING, AND PARTICIPANTS: Individual patient-level data from 29 centers were collected, including metastatic UC and first-line cisplatin- or carboplatin-based chemotherapy administered between January 2006 and January 2011...
October 8, 2016: European Urology
Jorge D Ramos, Martin F Casey, Aristotelis Bamias, Ugo De Giorgi, Joaquim Bellmunt, Lauren C Harshman, Sylvain Ladoire, Yu-Ning Wong, Ajjai S Alva, Jonathan E Rosenberg, Matthew D Galsky, Evan Y Yu
BACKGROUND: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. METHODS: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible...
September 16, 2016: Clinical and Applied Thrombosis/hemostasis
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason, Henk G van der Poel, Theo H van der Kwast, Olivier Rouvière, Thomas Wiegel, Nicolas Mottet
OBJECTIVE: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature...
August 31, 2016: European Urology
Stephanie A Mullane, Joaquim Bellmunt
PURPOSE OF REVIEW: Immunotherapy in urological cancer has made substantial progress during the last 20 years, but recent advances in immunotherapy have completely transformed the present treatment landscape. In this review, we summarize major clinical achievements of immunotherapy in genitourinary cancers, as well as address potential new directions for these therapies, including new agents, combinations, and biomarkers. RECENT FINDINGS: Recently, nivolumab and atezolizumab have joined sipuleucel-T as Food and Drug Administration-approved therapies in urological malignancies...
November 2016: Current Opinion in Urology
Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, Erik Briers, Marcus G Cumberbatch, Maria De Santis, Nicola Fossati, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason, Vsevolod B Matveev, Paul C Moldovan, Roderick C N van den Bergh, Thomas Van den Broeck, Henk G van der Poel, Theo H van der Kwast, Olivier Rouvière, Ivo G Schoots, Thomas Wiegel, Philip Cornford
OBJECTIVE: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence...
August 25, 2016: European Urology
Ellen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, Nikolay Budnik, Pawel J Wiechno, Cora N Sternberg, Kevin Doner, Joaquim Bellmunt, John M Burke, Maria Ochoa de Olza, Ananya Choudhury, Juergen E Gschwend, Evgeny Kopyltsov, Aude Flechon, Nicolas van As, Nadine Houede, Debora Barton, Abderrahim Fandi, Ulf Jungnelius, Shaoyi Li, Jack Shiansong Li, Ronald de Wit
Importance: The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it is beneficial for patients to continue treatment upon 6 cycles. Objective: To investigate whether the number of docetaxel cycles administered to patients deriving clinical benefit was an independent prognostic factor for overall survival (OS) in a post hoc analysis of the Mainsail trial...
August 25, 2016: JAMA Oncology
Nicholas J Vogelzang, Karim Fizazi, John M Burke, Ronald De Wit, Joaquim Bellmunt, Thomas E Hutson, Edward Crane, William R Berry, Kevin Doner, John D Hainsworth, Pawel J Wiechno, Kejian Liu, Michelle F Waldman, Anita Gandhi, Debora Barton, Ulf Jungnelius, Abderrahim Fandi, Cora N Sternberg, Daniel P Petrylak
: Elevated circulating tumor cell (CTC) blood levels (≥5 cells/7.5ml) convey a negative prognosis in metastatic castration-resistant prostate cancer but their prognostic significance in patients receiving chemotherapy is uncertain. The association between CTC counts (at baseline or after treatment), overall survival (OS), and response to docetaxel with lenalidomide was evaluated in a 208-patient subset from the MAINSAIL trial, which compared docetaxel-prednisone-lenalidomide and docetaxel-prednisone-placebo in metastatic castration-resistant prostate cancer patients...
August 10, 2016: European Urology
Andre P Fay, Guillermo de Velasco, Thai H Ho, Eliezer M Van Allen, Bradley Murray, Laurence Albiges, Sabina Signoretti, A Ari Hakimi, Melissa L Stanton, Joaquim Bellmunt, David F McDermott, Michael B Atkins, Levi A Garraway, David J Kwiatkowski, Toni K Choueiri
Advances in next-generation sequencing have provided a unique opportunity to understand the biology of disease and mechanisms of sensitivity or resistance to specific agents. Renal cell carcinoma (RCC) is a heterogeneous disease and highly variable clinical responses have been observed with vascular endothelial growth factor (VEGF)-targeted therapy (VEGF-TT). We hypothesized that whole-exome sequencing analysis might identify genotypes associated with extreme response or resistance to VEGF-TT in metastatic (mRCC)...
July 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Seth P Lerner, Dean F Bajorin, Colin P Dinney, Jason A Efstathiou, Susan Groshen, Noah M Hahn, Donna Hansel, David Kwiatkowski, Michael O'Donnell, Jonathan Rosenberg, Robert Svatek, Jeffrey S Abrams, Hikmat Al-Ahmadie, Andrea B Apolo, Joaquim Bellmunt, Margaret Callahan, Eugene K Cha, Charles Drake, Jonathan Jarow, Ashish Kamat, William Kim, Margaret Knowles, Bhupinder Mann, Luigi Marchionni, David McConkey, Lisa McShane, Nilsa Ramirez, Andrew Sharabi, Arlene H Sharpe, David Solit, Catherine M Tangen, Abdul Tawab Amiri, Eliezer Van Allen, Pamela J West, J A Witjes, Diane Zipursky Quale
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and multi-disciplinary group of clinical and research stakeholders and included leaders from NCI, FDA, National Clinical Trials Network (NCTN), advocacy and the pharmaceutical and biotech industry. The meeting goals and objectives were to: 1) create a collaborative environment in which the greater bladder research community can pursue future optimally designed novel clinical trials focused on the theme of molecular targeted and immune-based therapies in NMIBC; 2) frame the clinical and translational questions that are of highest priority; and 3) develop two clinical trial designs focusing on immunotherapy and molecular targeted therapy...
2016: Bladder Cancer
Joaquim Bellmunt, Nicolas Mottet, Maria De Santis
No abstract text is available yet for this article.
March 2016: EJC Supplements: EJC
Joaquim Bellmunt, Chensheng Willa Zhou, Stephanie A Mullane, Lillian Werner, Mary-Ellen Taplin, André P Fay, Toni K Choueiri, Anna Orsola, David Y Takeda, William C Hahn, Jaegil Kim, Guru Sonpavde, Michaela Bowden
BACKGROUND: Tumour expression of selected microRNAs (miRs) correlates with cisplatin efficacy in multiple cancers. We investigated the role of selected miRs in patients receiving cisplatin-based therapy for advanced urothelial carcinoma (UC). METHODS: RNA was extracted from formalin-fixed paraffin-embedded tumour from 83 advanced UC patients who received cisplatin. A miR panel based on relevance for platinum sensitivity and UC was studied by quantitative reverse transcription quantitative PCR (RT-qPCR)...
June 28, 2016: British Journal of Cancer
Andrea Necchi, Gregory R Pond, Daniele Raggi, Patrizia Giannatempo, Nicholas J Vogelzang, Petros Grivas, Matthew D Galsky, Joaquim Bellmunt, Guru Sonpavde
Although gemcitabine plus carboplatin (GCa) is the conventional first-line chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma, its results are suboptimal. A meta-analysis evaluated the results of gemcitabine with either carboplatin or a taxane (GT). Literature was searched for studies including GT (paclitaxel or docetaxel) and GCa. We pooled trial level data including response-rate, progression-free survival, overall survival (OS), and Grade 3 to 4 side effects. Trial characteristics and outcomes were univariably compared between GT and GCa...
May 27, 2016: Clinical Genitourinary Cancer
David Liu, Elizabeth R Plimack, Jean Hoffman-Censits, Levi A Garraway, Joaquim Bellmunt, Eliezer Van Allen, Jonathan E Rosenberg
No abstract text is available yet for this article.
August 1, 2016: JAMA Oncology
Stephanie A Mullane, Lillian Werner, Jonathan Rosenberg, Sabina Signoretti, Marcella Callea, Toni K Choueiri, Gordon J Freeman, Joaquim Bellmunt
Metastatic urothelial carcinoma (mUC) has a very high mutational rate and is associated with an APOBEC mutation signature. We examined the correlation of APOBEC expression with overall survival (OS) and PD-L1 expression in a cohort of 73 mUC patients. mRNA expression of APOBEC3 family of genes (A3A, A3B, A3C, A3F_a, A3F_b, A3G, A3H) was measured using Nanostring. PD-L1 expression, evaluated by immunohistochemistry, on tumor infiltrating mononuclear cells (TIMCs) and tumor cells was scored from 0 to 4, with 2-4 being positive...
2016: Scientific Reports
Thomas Seisen, Maxine Sun, Jeffrey J Leow, Mark A Preston, Alexander P Cole, Francisco Gelpi-Hammerschmidt, Nawar Hanna, Christian P Meyer, Adam S Kibel, Stuart R Lipsitz, Paul L Nguyen, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
PURPOSE: Evidence from studies of other malignancies has indicated that aggressive local treatment (LT), even in the presence of metastatic disease, is beneficial. Against a backdrop of stagnant mortality rates for metastatic urothelial carcinoma of the bladder (mUCB) at presentation, we hypothesized that high-intensity LT of primary tumor burden, defined as the receipt of radical cystectomy or ≥ 50 Gy of radiation therapy delivered to the bladder, affects overall survival (OS). PATIENTS AND METHODS: We identified 3,753 patients within the National Cancer Data Base who received multiagent systemic chemotherapy combined with high-intensity versus conservative LT for primary mUCB...
June 6, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Rana R McKay, Guillermo De Velasco, Lillian Werner, Joaquim Bellmunt, Lauren Harshman, Christopher Sweeney, Jonathan E Rosenberg, Michelle Hirsch, Sabina Signoretti, Eliezer M Van Allen, Meghara Walsh, Ulka Vaishampayan, David F McDermott, Toni K Choueiri
BACKGROUND: The phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is dysregulated in patients with metastatic renal cell carcinoma (mRCC). Buparlisib is a pan-PI3K inhibitor with activity in advanced solid tumors. The primary objective of the current study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of buparlisib and bevacizumab in patients with mRCC. Secondary objectives included efficacy, biomarker discovery, and additional toxicity...
August 1, 2016: Cancer
Paloma Cejas, Lewyn Li, Nicholas K O'Neill, Melissa Duarte, Prakash Rao, Michaela Bowden, Chensheng W Zhou, Marta Mendiola, Emilio Burgos, Jaime Feliu, Juan Moreno-Rubio, Héctor Guadalajara, Víctor Moreno, Damián García-Olmo, Joaquim Bellmunt, Stephanie Mullane, Michelle Hirsch, Christopher J Sweeney, Andrea Richardson, X Shirley Liu, Myles Brown, Ramesh A Shivdasani, Henry W Long
Extensive cross-linking introduced during routine tissue fixation of clinical pathology specimens severely hampers chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) analysis from archived tissue samples. This limits the ability to study the epigenomes of valuable, clinically annotated tissue resources. Here we describe fixed-tissue chromatin immunoprecipitation sequencing (FiT-seq), a method that enables reliable extraction of soluble chromatin from formalin-fixed paraffin-embedded (FFPE) tissue samples for accurate detection of histone marks...
June 2016: Nature Medicine
Guru Sonpavde, Joaquim Bellmunt
No abstract text is available yet for this article.
June 2016: Nature Reviews. Urology
Georgios Gakis, Tina Schubert, Mehrdad Alemozaffar, Joaquim Bellmunt, Bernard H Bochner, Steven A Boorjian, Siamak Daneshmand, William C Huang, Tsunenori Kondo, Badrinath R Konety, Maria Pilar Laguna, Surena F Matin, Arlene O Siefker-Radtke, Shahrokh F Shariat, Arnulf Stenzl
PURPOSE: To provide a comprehensive overview and update of the joint consultation of the International Consultation on Urological Diseases (ICUD) and Société Internationale d'Urologie for the treatment of localized high-risk upper tract urothelial carcinoma (UTUC). METHODS: A detailed analysis of the literature was conducted reporting on treatment modalities and outcomes in localized high-risk UTUC. An international, multidisciplinary expert committee evaluated and graded the data according to the Oxford System of Evidence-based Medicine modified by the ICUD...
April 4, 2016: World Journal of Urology
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta M Retz, Petros Grivas, Richard W Joseph, Matthew D Galsky, Mark T Fleming, Daniel P Petrylak, Jose Luis Perez-Gracia, Howard A Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M Frampton, Na Cui, Sanjeev Mariathasan, Oyewale Abidoye, Gregg D Fine, Robert Dreicer
BACKGROUND: Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab, an engineered humanised immunoglobulin G1 monoclonal antibody that binds selectively to programmed death ligand 1 (PD-L1), in this patient population. METHODS: For this multicentre, single-arm, two-cohort, phase 2 trial, patients (aged ≥18 years) with inoperable locally advanced or metastatic urothelial carcinoma whose disease had progressed after previous platinum-based chemotherapy were enrolled from 70 major academic medical centres and community oncology practices in Europe and North America...
May 7, 2016: Lancet
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"